<DOC>
	<DOCNO>NCT02378961</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , efficacy GS-9857 plus sofosbuvir ( SOF ) /velpatasvir ( VEL ) fix dose combination ( FDC ) adults chronic non genotype 1 hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Safety Efficacy GS-9857 Plus Sofosbuvir/Velpatasvir Fixed Dose Combination Adults With Chronic Non-Genotype 1 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Individuals chronic HCV infection HCV RNA â‰¥10^4 IU/mL screen HCV genotype 2 , 3 , 4 , 5 , 6 Cirrhosis determination ; liver biopsy may require Screening laboratory value within define threshold Use two contraception method female childbearing potential sexually active male Pregnant nursing female Current prior history hepatic decompensation Hepatocellular carcinoma ( HCC ) clinically significant malignancy Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) History clinically significant illness medical disorder may interfere individual 's treatment , assessment compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>